Drug
Av-101 clinical trials
Also written AV-101 and L-4-chlorokynurenine.
- studies test it
- 8
- open now
- 0
- in phase 3
- 2
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
8 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
VistaGen Therapeutics, Inc. (4) · Aerovate Therapeutics (2) · National Institute of Mental Health (NIMH) (1) · Marijn Lijffijt, PhD (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses av-101 is read from its arms, and is right about nine times in ten.
Testing it · 8
- Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)TerminatedPhase 3Aerovate TherapeuticsNCT05557942Written as AV-101
- A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)TerminatedPhase 2/3Aerovate TherapeuticsNCT05036135Written as AV-101
- Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive DisorderCompletedPhase 2National Institute of Mental Health (NIMH)NCT02484456Written as AV 101 (4-Chlorokynurenine)
- AV-101 Alone and in Combination With Probenecid in Healthy SubjectsStatus unknownPhase 1VistaGen Therapeutics, Inc.NCT05280054Written as AV-101
- Electrophysiological Biomarkers of AV-101CompletedPhase 1/2Marijn Lijffijt, PhDNCT03583554Written as AV-101 720 mg
- AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaStatus unknownPhase 2VistaGen Therapeutics, Inc.NCT04147949Written as AV-101
- AV-101 as Adjunct Antidepressant Therapy in Patients With Major DepressionCompletedPhase 2VistaGen Therapeutics, Inc.NCT03078322Written as AV-101
- Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy VolunteersCompletedPhase 1VistaGen Therapeutics, Inc.NCT01483846Written as AV-101
Codes
What other systems call av-101 · ClinicalTrials.gg INT002865
- UNII (FDA) 77XLH9L40BAV-101One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 77XLH9L40B | AV-101 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.